Episode 97: Spotlight: Advanced Breast Cancer - Which CDK4/6 Inhibitor is Best?

It is a tale as old as time, as old as the stars, the heavens and human consciousness itself. Okay, we're exaggerating a bit, but for as long as pharmacology and capitalism have been joined at the hip, the question of "which drug is best" has been at or near the forefront of medical decision-making. With the development of standardised clinical trials and the difficulty of conducting direct head-to-head comparisons, this question has become more difficult to answer conclusively. Nowhere is this epitomised better than with the triptych of available CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib. A lot of ink and pixels have been devoted to comparing the pivotal trials of these three equally pivotal agents: PALOMA-2, MONALEESA-2 and MONARCH-3, respectively. However, Josh and Michael have brought the definitive and not-at-all rambling answer to this question. Listen on to find out!